Toxicology

Up to 30 percent of patients with B cell malignancies such as lymphoma relapse after CAR T cell treatment, partly because their lymphoma cells stop expressing the target antigen

According to a recent review, the three drugs may be underused in part because access is limited by some legal requirements regarding who can write prescriptions